A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

被引：0
|
作者：
Kelly, K
Mikhaeel-Kamel, N
Pan, ZX
Murphy, J
Prindiville, S
Bunn, PA
机构：
[1] Univ Colorado, Hlth Sci Ctr, Ctr Canc, Div Med Oncol, Denver, CO 80262 USA
[2] Univ Colorado, Ctr Canc, Lung Canc Program, Denver, CO 80262 USA
[3] Univ Colorado, Ctr Canc, Dept Prevent Med & Biostat, Denver, CO 80262 USA
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.
引用
收藏
页码：3474 / 3479
页数：6
相关论文
共 50 条
  • [41] Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer
    Yanagitani, Noriko
    Tsuchiya, Satoshi
    Kaira, Kyoichi
    Sunaga, Noriaki
    Tsuchiya, Yukiko
    Sato, Koji
    Watanabe, Satoru
    Nomura, Shiro
    Sakai, Shuzo
    Saito, Ryusei
    Mori, Masatomo
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (05): : 487 - 491
  • [42] Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer
    Takayama, Koichi
    Ichiki, Masao
    Tokunaga, Shoji
    Inoue, Koji
    Kawasaki, Masayuki
    Uchino, Junji
    Nakanishi, Yoichi
    ONCOLOGIST, 2019, 24 (11): : 1420 - +
  • [43] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study
    Piantedosi, F. V.
    Caputo, F.
    Mazzarella, G.
    Gilli, M.
    Pontillo, A.
    D'Agostino, D.
    Campbell, S.
    Marsico, S. A.
    Bianco, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 803 - 807
  • [44] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study
    F. V. Piantedosi
    F. Caputo
    G. Mazzarella
    M. Gilli
    A. Pontillo
    D. D’Agostino
    S. Campbell
    S. A. Marsico
    A. Bianco
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 803 - 807
  • [45] Phase I/II trial of carboplatin (CBDCA)/weekly paclitaxel in patients with advanced non-small cell lung cancer in Japanese population: WJTOG 9907
    Bessho, A
    Saka, H
    Kitaguchi, S
    Yamamoto, M
    Shinkai, T
    Fukuoka, M
    Ariyoshi, Y
    LUNG CANCER, 2005, 49 : S236 - S236
  • [46] Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy
    Yoh, Kiyotaka
    Kubota, Kaoru
    Kakinuma, Ryutaro
    Ohmatsu, Hironobu
    Goto, Koichi
    Niho, Seiji
    Saijo, Nagahiro
    Nishiwaki, Yutaka
    LUNG CANCER, 2007, 58 (01) : 73 - 79
  • [47] Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
    Tell, Roger
    Sederholm, Christer
    Klintenberg, Claes
    Franksson, Lars
    Branden, Eva
    Hillerdal, Gunnar
    Lonn, Ulf
    Linden, Carl-Johan
    Ewers, Sven-Borje
    Lamberg, Kristina
    Mrazek, Eva
    Loden, Britta
    Sjogren, Anders
    Linne, Thomas
    Friesland, Signe
    Sirzen, Florin
    ANTICANCER RESEARCH, 2008, 28 (5B) : 2851 - 2857
  • [48] A phase I study of gemcitabine and carboplatin in non-small cell lung cancer
    Carmichael, J
    Allerheiligen, S
    Walling, J
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 55 - 59
  • [49] Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
    Minami S.
    Kijima T.
    Shiroyama T.
    Okafuji K.
    Hirashima T.
    Uchida J.
    Imamura F.
    Osaki T.
    Nakatani T.
    Ogata Y.
    Yamamoto S.
    Namba Y.
    Otsuka T.
    Tachibana I.
    Komuta K.
    Kawase I.
    BMC Research Notes, 6 (1)
  • [50] Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer
    Yun Fan
    Neng-ming Lin
    Sheng-lin Ma
    Lü-hong Luo
    Luo Fang
    Zhi-yu Huang
    Hai-feng Yu
    Feng-qin Wu
    Acta Pharmacologica Sinica, 2010, 31 : 746 - 752
12345